Victoza (active ingredient liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist medication manufactured by Novo ...

The hidden cost GLP boom shows total payments rose sharply from 2017-2022 despite lower out-of-pocket costs, impacting insurers and Medicare programs.

Live updates: Trump called FIFA chief over USA player’s red card; Johnson warns of more ‘Mamdanis’ 'No one is above the law': ...

This Kansas City, Kansas, advocate calls for Congress to cap out-of-pocket costs at $35 a month. | Opinion ...

A routine medical examination delivered a life-altering diagnosis that would cost one young labourer his sight, his health ...

Diabetes care is changing. New guidelines emphasize that managing emotional distress is just as vital as tracking your ...

Dallas expected to save $12 million on employee healthcare this year, but rising GLP-1 drug use and high-cost claims now have ...

About a dozen states offer “medically tailored meals” to people with conditions such as diabetes and heart disease who get ...

By Nqobile Dludla JOHANNESBURG, July 17 (Reuters) - Novo Nordisk will launch a more affordable authorised copy of its Ozempic diabetes drug in South Africa later this month, partnering with healthcare ...

As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new ...

Novo Nordisk India launched Awiqli, the first once-weekly basal insulin for diabetes, reducing injections from daily to ...

Employers are bracing for what could be the highest rise in health insurance premiums in 16 years, driving up the cost of ...